{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:56:45Z","timestamp":1792803405583,"version":"4.5.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00281-025-01065-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:09:42Z","timestamp":1762848582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Systemic sclerosis: pathogenic mechanisms and their implications for treatment"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8558","authenticated-orcid":false,"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lecureur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953\u20131962. https:\/\/doi.org\/10.1002\/art.37988","journal-title":"Arthritis Rheum"},{"key":"1065_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","volume":"18","author":"D Fang","year":"2022","unstructured":"Fang D, Chen B, Lescoat A et al (2022) Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol 18:683\u2013693. https:\/\/doi.org\/10.1038\/s41584-022-00864-7","journal-title":"Nat Rev Rheumatol"},{"key":"1065_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","volume":"170","author":"B Hinz","year":"2007","unstructured":"Hinz B, Phan SH, Thannickal VJ et al (2007) The myofibroblast: one function, multiple origins. Am J Pathol 170:1807\u20131816. https:\/\/doi.org\/10.2353\/ajpath.2007.070112","journal-title":"Am J Pathol"},{"key":"1065_CR5","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76:1897\u20131905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448","journal-title":"Ann Rheum Dis"},{"key":"1065_CR6","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2665-9913(19)30038-4","volume":"1","author":"A Lescoat","year":"2019","unstructured":"Lescoat A, Cavalin C, Ehrlich R et al (2019) The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. Lancet Rheumatol 1:e257\u2013e264. https:\/\/doi.org\/10.1016\/S2665-9913(19)30038-4","journal-title":"Lancet Rheumatol"},{"key":"1065_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2013.5079","volume":"149","author":"NM Fett","year":"2013","unstructured":"Fett NM (2013) Morphea (Localized Scleroderma). JAMA Dermatol 149:1124\u20131124. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5079","journal-title":"JAMA Dermatol"},{"key":"1065_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.5809","volume":"157","author":"S Prasad","year":"2021","unstructured":"Prasad S, Zhu JL, Schollaert-Fitch K et al (2021) An evaluation of the performance of current morphea subtype classifications. JAMA Dermatol 157:1\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5809","journal-title":"JAMA Dermatol"},{"key":"1065_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","volume":"18","author":"RM Laxer","year":"2006","unstructured":"Laxer RM, Zulian F (2006) Localized scleroderma. Curr Opin Rheumatol 18:606\u2013613. https:\/\/doi.org\/10.1097\/01.bor.0000245727.40630.c3","journal-title":"Curr Opin Rheumatol"},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative: ACR\/EULAR Classification Criteria for SSc. Arthritis Rheum 65:2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098","journal-title":"Arthritis Rheum"},{"key":"1065_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal R, Ringold S, Khanna D et al (2015) Distinctions between diagnostic and classification criteria? Arthritis Care Res 67:891\u2013897. https:\/\/doi.org\/10.1002\/acr.22583","journal-title":"Arthritis Care Res"},{"key":"1065_CR12","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","volume":"3","author":"S Bellando-Randone","year":"2021","unstructured":"Bellando-Randone S, Galdo FD, Lepri G et al (2021) Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol 3:e834\u2013e843. https:\/\/doi.org\/10.1016\/S2665-9913(21)00244-7","journal-title":"Lancet Rheumatol"},{"key":"1065_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1351675","author":"K Romanowska-Pr\u00f3chnicka","year":"2024","unstructured":"Romanowska-Pr\u00f3chnicka K, Dziewit M, Lesiak A et al (2024) Scleroderma and scleroderma-like syndromes. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1351675","journal-title":"Front Immunol"},{"issue":"21","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"00199","DOI":"10.1016\/j.semarthrit.2021.11.003","volume":"S0049\u20130172","author":"A Lescoat","year":"2021","unstructured":"Lescoat A, Murphy SL, Chen YT et al (2021) Symptom experience of limited cutaneous systemic sclerosis from the Patients\u2019 perspective: A qualitative study\u2730,\u2730\u2730,\u2605,\u2605\u2605. Semin Arthritis Rheum S0049\u20130172(21):00199\u201300202. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.003","journal-title":"Semin Arthritis Rheum"},{"key":"1065_CR15","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"1065_CR16","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573\u20131576","journal-title":"J Rheumatol"},{"key":"1065_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.1729","author":"A Lescoat","year":"2023","unstructured":"Lescoat A, Huang S, Carreira PE et al (2023) Cutaneous manifestations, clinical characteristics, and prognosis of patients with systemic sclerosis sine scleroderma: data from the international EUSTAR database. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2023.1729","journal-title":"JAMA Dermatol"},{"key":"1065_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/kel451","volume":"46","author":"F Verrecchia","year":"2007","unstructured":"Verrecchia F, Laboureau J, Verola O et al (2007) Skin involvement in scleroderma\u2013where histological and clinical scores meet. Rheumatology (Oxford) 46:833\u2013841. https:\/\/doi.org\/10.1093\/rheumatology\/kel451","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR19","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","volume":"73","author":"T Minier","year":"2014","unstructured":"Minier T, Guiducci S, Bellando-Randone S et al (2014) Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73:2087\u20132093. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203716","journal-title":"Ann Rheum Dis"},{"key":"1065_CR20","first-page":"1281","volume":"22","author":"P Clements","year":"1995","unstructured":"Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281\u20131285","journal-title":"J Rheumatol"},{"key":"1065_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","volume":"43","author":"PJ Clements","year":"2000","unstructured":"Clements PJ, Hurwitz EL, Wong WK et al (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43:2445\u20132454. https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11%3c2445::AID-ANR11%3e3.0.CO;2-Q","journal-title":"Arthritis Rheum"},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1093\/rheumatology\/keab075","volume":"60","author":"RT Domsic","year":"2021","unstructured":"Domsic RT, Gao S, Laffoon M et al (2021) Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology (Oxford) 60:4662\u20134670. https:\/\/doi.org\/10.1093\/rheumatology\/keab075","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02548-1","volume":"23","author":"S Jaafar","year":"2021","unstructured":"Jaafar S, Lescoat A, Huang S et al (2021) Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther 23:170. https:\/\/doi.org\/10.1186\/s13075-021-02548-1","journal-title":"Arthritis Res Ther"},{"key":"1065_CR24","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10067-021-05598-7","volume":"40","author":"SL Murphy","year":"2021","unstructured":"Murphy SL, Lescoat A, Alore M et al (2021) How do patients define Raynaud\u2019s phenomenon? Differences between primary and secondary disease. Clin Rheumatol 40:1611\u20131616. https:\/\/doi.org\/10.1007\/s10067-021-05598-7","journal-title":"Clin Rheumatol"},{"key":"1065_CR25","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/rheumatology\/keu533","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Moore T, O\u2019Leary N et al (2015) A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders. Rheumatology (Oxford) 54:1435\u20131442. https:\/\/doi.org\/10.1093\/rheumatology\/keu533","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR26","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/art.39718","volume":"68","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Herrick AL, Distler O et al (2016) Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study. Arthritis Rheumatol 68:2527\u20132539. https:\/\/doi.org\/10.1002\/art.39718","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/art.40799","volume":"71","author":"A Lescoat","year":"2019","unstructured":"Lescoat A, Yelnik CM, Coiffier G et al (2019) Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross-sectional study. Arthritis Rheumatol 71:983\u2013990. https:\/\/doi.org\/10.1002\/art.40799","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5301\/jsrd.5000236","volume":"2","author":"YA Suliman","year":"2017","unstructured":"Suliman YA, Bruni C, Johnson SR et al (2017) Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition. J Scleroderma Relat Disord 2:115\u2013120. https:\/\/doi.org\/10.5301\/jsrd.5000236","journal-title":"J Scleroderma Relat Disord"},{"key":"1065_CR29","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/acr.23413","volume":"70","author":"A Lescoat","year":"2018","unstructured":"Lescoat A, Coiffier G, de Carlan M et al (2018) Combination of capillaroscopic and ultrasonographic evaluations in systemic sclerosis: results of a cross-sectional study. Arthritis Care Res Hoboken 70:938\u2013943. https:\/\/doi.org\/10.1002\/acr.23413","journal-title":"Arthritis Care Res Hoboken"},{"key":"1065_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.semarthrit.2016.05.008","volume":"46","author":"A Valenzuela","year":"2016","unstructured":"Valenzuela A, Baron M, Herrick AL et al (2016) Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: a Scleroderma Clinical Trials Consortium study. Semin Arthritis Rheum 46:344\u2013349. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.008","journal-title":"Semin Arthritis Rheum"},{"key":"1065_CR31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jamadermatol.2018.0916","volume":"154","author":"M Jouvray","year":"2018","unstructured":"Jouvray M, Launay D, Dubucquoi S et al (2018) Whole-body distribution and clinical association of telangiectases in systemic sclerosis. JAMA Dermatol 154:796\u2013805. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0916","journal-title":"JAMA Dermatol"},{"key":"1065_CR32","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"A-M Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold A-M, Maher TM, Philpot EE et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology 2:e71-83. https:\/\/doi.org\/10.1016\/S2665-9913(19)30144-4","journal-title":"The Lancet Rheumatology"},{"key":"1065_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3899\/jrheum.121390","volume":"40","author":"A-M Hoffmann-Vold","year":"2013","unstructured":"Hoffmann-Vold A-M, Molberg \u00d8, Midtvedt \u00d8 et al (2013) Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 40:1127\u20131133. https:\/\/doi.org\/10.3899\/jrheum.121390","journal-title":"J Rheumatol"},{"key":"1065_CR34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK et al (2015) An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976\u2013987. https:\/\/doi.org\/10.1183\/13993003.00150-2015","journal-title":"Eur Respir J"},{"key":"1065_CR35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788\u2013824. https:\/\/doi.org\/10.1164\/rccm.2009-040GL","journal-title":"Am J Respir Crit Care Med"},{"issue":"14","key":"1065_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351(14):1425\u20131436. https:\/\/doi.org\/10.1056\/NEJMra040291","journal-title":"N Engl J Med"},{"key":"1065_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/23971983231163413","volume":"8","author":"C Bruni","year":"2023","unstructured":"Bruni C, Buch MH, Djokovic A et al (2023) Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation\/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. Journal of Scleroderma and Related Disorders 8:169\u2013182. https:\/\/doi.org\/10.1177\/23971983231163413","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"1065_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41584-022-00900-6","volume":"19","author":"ZH McMahan","year":"2023","unstructured":"McMahan ZH, Kulkarni S, Chen J et al (2023) Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nat Rev Rheumatol 19:166\u2013181. https:\/\/doi.org\/10.1038\/s41584-022-00900-6","journal-title":"Nat Rev Rheumatol"},{"key":"1065_CR39","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00296-011-1988-6","volume":"32","author":"T Schmeiser","year":"2012","unstructured":"Schmeiser T, Saar P, Jin D et al (2012) Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int 32:2471\u20132478. https:\/\/doi.org\/10.1007\/s00296-011-1988-6","journal-title":"Rheumatol Int"},{"key":"1065_CR40","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1093\/rheumatology\/kez435","volume":"58","author":"H Yamashita","year":"2019","unstructured":"Yamashita H, Kamei R, Kaneko H (2019) Classifications of scleroderma renal crisis and reconsideration of its pathophysiology. Rheumatology 58:2099\u20132106. https:\/\/doi.org\/10.1093\/rheumatology\/kez435","journal-title":"Rheumatology"},{"key":"1065_CR41","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/rheumatology\/key214","volume":"57","author":"A Lescoat","year":"2018","unstructured":"Lescoat A, Ballerie A, Belhomme N et al (2018) Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study. Rheumatology (Oxford) 57:2012\u20132021. https:\/\/doi.org\/10.1093\/rheumatology\/key214","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR42","doi-asserted-by":"publisher","first-page":"SI1","DOI":"10.1093\/rheumatology\/keac412","volume":"62","author":"F Zimmermann","year":"2023","unstructured":"Zimmermann F, Robin F, Caillault L et al (2023) Sicca syndrome in systemic sclerosis: a narrative review on a neglected issue. Rheumatology (Oxford). 62:SI1-11. https:\/\/doi.org\/10.1093\/rheumatology\/keac412","journal-title":"Rheumatology (Oxford)."},{"key":"1065_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae086","volume":"8","author":"A Chen","year":"2024","unstructured":"Chen A, Lax SJ, Grainge MJ et al (2024) Prevalence, incidence, and mortality of Raynaud\u2019s phenomenon, Sj\u00f6gren\u2019s syndrome and scleroderma: an umbrella review of systematic reviews. Rheumatol Adv Pract 8:rkae086. https:\/\/doi.org\/10.1093\/rap\/rkae086","journal-title":"Rheumatol Adv Pract"},{"key":"1065_CR44","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar M, Rossides M, Westerlind H et al (2021) Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) 60:3121\u20133133. https:\/\/doi.org\/10.1093\/rheumatology\/keab190","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109267","volume":"248","author":"J Tian","year":"2023","unstructured":"Tian J, Kang S, Zhang D et al (2023) Global, regional, and national incidence and prevalence of systemic sclerosis. Clin Immunol 248:109267. https:\/\/doi.org\/10.1016\/j.clim.2023.109267","journal-title":"Clin Immunol"},{"key":"1065_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/annrheumdis-2014-206386","volume":"75","author":"M Elhai","year":"2016","unstructured":"Elhai M, Avouac J, Walker UA et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75:163\u2013169. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206386","journal-title":"Ann Rheum Dis"},{"key":"1065_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa026","author":"H Fretheim","year":"2020","unstructured":"Fretheim H, Halse A-K, Seip M et al (2020) Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa026","journal-title":"Rheumatology"},{"key":"1065_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","volume":"72","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova SI, Sari A, Harvey JC et al (2020) Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol 72:465\u2013476. https:\/\/doi.org\/10.1002\/art.41153","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR49","doi-asserted-by":"publisher","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","volume":"4","author":"M Elhai","year":"2022","unstructured":"Elhai M, Sritharan N, Boubaya M et al (2022) Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. Lancet Rheumatol 4:e785\u2013e794. https:\/\/doi.org\/10.1016\/S2665-9913(22)00217-X","journal-title":"Lancet Rheumatol"},{"key":"1065_CR50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","volume":"77","author":"AL Herrick","year":"2018","unstructured":"Herrick AL, Peytrignet S, Lunt M et al (2018) Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis 77:563\u2013570. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211912","journal-title":"Ann Rheum Dis"},{"key":"1065_CR51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/art.40906","volume":"71","author":"V Sobanski","year":"2019","unstructured":"Sobanski V, Giovannelli J, Allanore Y et al (2019) Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis. Arthritis Rheumatol 71:1553\u20131570. https:\/\/doi.org\/10.1002\/art.40906","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002696","volume":"3","author":"A Milano","year":"2008","unstructured":"Milano A, Pendergrass SA, Sargent JL et al (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3:e2696. https:\/\/doi.org\/10.1371\/journal.pone.0002696","journal-title":"PLoS One"},{"issue":"9830","key":"1065_CR53","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(12)60235-9","volume":"379","author":"CC Leung","year":"2012","unstructured":"Leung CC, Yu ITS, Chen W (2012) Silicosis. Lancet 379(9830):2008\u20132018. https:\/\/doi.org\/10.1016\/S0140-6736(12)60235-9","journal-title":"Lancet"},{"key":"1065_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S2213-2600(19)30078-5","volume":"7","author":"The Lancet Respiratory Medicine null","year":"2019","unstructured":"The Lancet Respiratory Medicine null (2019) The world is failing on silicosis. Lancet Respir Med 7:283. https:\/\/doi.org\/10.1016\/S2213-2600(19)30078-5","journal-title":"Lancet Respir Med"},{"key":"1065_CR55","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/occmed\/kqv073","volume":"65","author":"O Shtraichman","year":"2015","unstructured":"Shtraichman O, Blanc PD, Ollech JE et al (2015) Outbreak of autoimmune disease in silicosis linked to artificial stone. Occup Med (Lond) 65:444\u2013450. https:\/\/doi.org\/10.1093\/occmed\/kqv073","journal-title":"Occup Med (Lond)"},{"key":"1065_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa287","author":"SH Boudigaard","year":"2021","unstructured":"Boudigaard SH, Schl\u00fcnssen V, Vestergaard JM et al (2021) Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study. Int J Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyaa287","journal-title":"Int J Epidemiol"},{"key":"1065_CR57","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1093\/rheumatology\/keac675","volume":"62","author":"C Cavalin","year":"2023","unstructured":"Cavalin C, Lescoat A, Sigaux J et al (2023) Crystalline silica exposure in patients with rheumatoid arthritis and systemic sclerosis: a nationwide cross-sectional survey. Rheumatology (Oxford) 62:2707\u20132715. https:\/\/doi.org\/10.1093\/rheumatology\/keac675","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jaut.2012.05.002","volume":"39","author":"FW Miller","year":"2012","unstructured":"Miller FW, Alfredsson L, Costenbader KH et al (2012) Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun 39:259\u2013271. https:\/\/doi.org\/10.1016\/j.jaut.2012.05.002","journal-title":"J Autoimmun"},{"key":"1065_CR59","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s10067-018-4045-y","volume":"37","author":"E De Decker","year":"2018","unstructured":"De Decker E, Vanthuyne M, Blockmans D et al (2018) High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis. Clin Rheumatol 37:1977\u20131982. https:\/\/doi.org\/10.1007\/s10067-018-4045-y","journal-title":"Clin Rheumatol"},{"key":"1065_CR60","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1136\/ard.2008.088419","volume":"67","author":"V Smith","year":"2008","unstructured":"Smith V, Vanthuyne M, Vander Cruyssen B et al (2008) Over-representation of construction-related occupations in male patients with systemic sclerosis. Ann Rheum Dis 67:1448\u20131450. https:\/\/doi.org\/10.1136\/ard.2008.088419","journal-title":"Ann Rheum Dis"},{"key":"1065_CR61","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.semarthrit.2020.08.014","volume":"50","author":"A Ballerie","year":"2020","unstructured":"Ballerie A, Cavalin C, Lederlin M et al (2020) Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis. Semin Arthritis Rheum 50:949\u2013956. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.014","journal-title":"Semin Arthritis Rheum"},{"key":"1065_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.984907","volume":"9","author":"A Muntyanu","year":"2022","unstructured":"Muntyanu A, Milan R, Rahme E et al (2022) Exposure to silica and systemic sclerosis: a retrospective cohort study based on the Canadian Scleroderma Research Group. Front Med 9:984907. https:\/\/doi.org\/10.3389\/fmed.2022.984907","journal-title":"Front Med"},{"key":"1065_CR63","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/rheumatology\/keaa446","volume":"59","author":"S Patel","year":"2020","unstructured":"Patel S, Morrisroe K, Proudman S et al (2020) Occupational silica exposure in an Australian systemic sclerosis cohort. Rheumatology (Oxford) 59:3900\u20133905. https:\/\/doi.org\/10.1093\/rheumatology\/keaa446","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR64","first-page":"97","volume":"34","author":"A Kettaneh","year":"2007","unstructured":"Kettaneh A, Al Moufti O, Tiev KP et al (2007) Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies. J Rheumatol 34:97\u2013103","journal-title":"J Rheumatol"},{"key":"1065_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102727","volume":"124","author":"C Ferri","year":"2021","unstructured":"Ferri C, Arcangeletti M-C, Caselli E et al (2021) Insights into the knowledge of complex diseases: environmental infectious\/toxic agents as potential etiopathogenetic factors of systemic sclerosis. J Autoimmun 124:102727. https:\/\/doi.org\/10.1016\/j.jaut.2021.102727","journal-title":"J Autoimmun"},{"key":"1065_CR66","first-page":"348","volume":"68","author":"M Radi\u0107","year":"2010","unstructured":"Radi\u0107 M, Martinovi\u0107 Kaliterna D, Radi\u0107 J (2010) Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis. Neth J Med 68:348\u2013353","journal-title":"Neth J Med"},{"key":"1065_CR67","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1073\/pnas.1906593116","volume":"117","author":"P Gourh","year":"2020","unstructured":"Gourh P, Safran SA, Alexander T et al (2020) HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proc Natl Acad Sci U S A 117:552\u2013562. https:\/\/doi.org\/10.1073\/pnas.1906593116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1065_CR68","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","volume":"10","author":"E L\u00f3pez-Isac","year":"2019","unstructured":"L\u00f3pez-Isac E, Acosta-Herrera M, Kerick M et al (2019) GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nat Commun 10:4955. https:\/\/doi.org\/10.1038\/s41467-019-12760-y","journal-title":"Nat Commun"},{"key":"1065_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15022-4","volume":"11","author":"JP Ray","year":"2020","unstructured":"Ray JP, de Boer CG, Fulco CP et al (2020) Prioritizing disease and trait causal variants at the TNFAIP3 locus using functional and genomic features. Nat Commun 11:1237. https:\/\/doi.org\/10.1038\/s41467-020-15022-4","journal-title":"Nat Commun"},{"key":"1065_CR70","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0000000000000735","volume":"32","author":"C Orvain","year":"2020","unstructured":"Orvain C, Assassi S, Avouac J et al (2020) Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr Opin Rheumatol 32:505\u2013514. https:\/\/doi.org\/10.1097\/BOR.0000000000000735","journal-title":"Curr Opin Rheumatol"},{"key":"1065_CR71","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1172\/JCI131700","volume":"130","author":"T Maehara","year":"2020","unstructured":"Maehara T, Kaneko N, Perugino CA et al (2020) Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest 130:2451\u20132464. https:\/\/doi.org\/10.1172\/JCI131700","journal-title":"J Clin Invest"},{"key":"1065_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109723","volume":"116","author":"N Bellamri","year":"2023","unstructured":"Bellamri N, Lelong M, Joannes A et al (2023) Effects of ruxolitinib on fibrosis in preclinical models of systemic sclerosis. Int Immunopharmacol 116:109723. https:\/\/doi.org\/10.1016\/j.intimp.2023.109723","journal-title":"Int Immunopharmacol"},{"key":"1065_CR73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/BOR.0000000000000959","volume":"35","author":"Y Kawaguchi","year":"2023","unstructured":"Kawaguchi Y, Kuwana M (2023) Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis. Curr Opin Rheumatol 35:309\u2013316. https:\/\/doi.org\/10.1097\/BOR.0000000000000959","journal-title":"Curr Opin Rheumatol"},{"key":"1065_CR74","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.4049\/jimmunol.0803705","volume":"182","author":"A Servettaz","year":"2009","unstructured":"Servettaz A, Goulvestre C, Kavian N et al (2009) Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 182:5855\u20135864. https:\/\/doi.org\/10.4049\/jimmunol.0803705","journal-title":"J Immunol"},{"key":"1065_CR75","doi-asserted-by":"publisher","unstructured":"Tsou P-S, Palisoc PJ, Flavahan NA, et al. Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma. Arthritis Rheumatol. Published Online First: 1 October 2020. https:\/\/doi.org\/10.1002\/art.41536","DOI":"10.1002\/art.41536"},{"key":"1065_CR76","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/art.30317","volume":"63","author":"Z Li","year":"2011","unstructured":"Li Z, Jimenez SA (2011) Protein kinase C\u03b4 and c-Abl kinase are required for transforming growth factor \u03b2 induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum 63:2473\u20132483. https:\/\/doi.org\/10.1002\/art.30317","journal-title":"Arthritis Rheum"},{"key":"1065_CR77","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","volume":"38","author":"P Dorfm\u00fcller","year":"2007","unstructured":"Dorfm\u00fcller P, Humbert M, Perros F et al (2007) Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38:893\u2013902. https:\/\/doi.org\/10.1016\/j.humpath.2006.11.022","journal-title":"Hum Pathol"},{"key":"1065_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn TA (2004) Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat Rev Immunol 4:583\u2013594. https:\/\/doi.org\/10.1038\/nri1412","journal-title":"Nat Rev Immunol"},{"key":"1065_CR79","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","volume":"45","author":"FK Tan","year":"2006","unstructured":"Tan FK, Zhou X, Mayes MD et al (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694\u2013702. https:\/\/doi.org\/10.1093\/rheumatology\/kei244","journal-title":"Rheumatology (Oxford)"},{"key":"1065_CR80","first-page":"1751","volume":"151","author":"C Mavalia","year":"1997","unstructured":"Mavalia C, Scaletti C, Romagnani P et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751\u20131758","journal-title":"Am J Pathol"},{"key":"1065_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26099-w","volume":"12","author":"A Kuzumi","year":"2021","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM et al (2021) Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun 12:5947. https:\/\/doi.org\/10.1038\/s41467-021-26099-w","journal-title":"Nat Commun"},{"key":"1065_CR82","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug B, Khanna D, Swindell WR et al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79:379\u2013386. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215894","journal-title":"Ann Rheum Dis"},{"key":"1065_CR83","doi-asserted-by":"publisher","first-page":"e5903","DOI":"10.1371\/journal.pone.0005903","volume":"4","author":"TRDJ Radstake","year":"2009","unstructured":"Radstake TRDJ, van Bon L, Broen J et al (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS ONE 4:e5903. https:\/\/doi.org\/10.1371\/journal.pone.0005903","journal-title":"PLoS ONE"},{"key":"1065_CR84","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2017.09.007","volume":"195","author":"C Chizzolini","year":"2018","unstructured":"Chizzolini C, Dufour AM, Brembilla NC (2018) Is there a role for IL-17 in the pathogenesis of systemic sclerosis? Immunol Lett 195:61\u201367. https:\/\/doi.org\/10.1016\/j.imlet.2017.09.007","journal-title":"Immunol Lett"},{"key":"1065_CR85","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/BOR.0000000000000835","volume":"33","author":"A Lescoat","year":"2021","unstructured":"Lescoat A, Lecureur V, Varga J (2021) Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. Curr Opin Rheumatol 33:463\u2013470. https:\/\/doi.org\/10.1097\/BOR.0000000000000835","journal-title":"Curr Opin Rheumatol"},{"key":"1065_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47083-y","volume":"13","author":"A Morozan","year":"2023","unstructured":"Morozan A, Joy S, Fujii U et al (2023) Superiority of systemic bleomycin to intradermal HOCl for the study of interstitial lung disease. Sci Rep 13:20577. https:\/\/doi.org\/10.1038\/s41598-023-47083-y","journal-title":"Sci Rep"},{"key":"1065_CR87","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","volume":"69","author":"N Dumoitier","year":"2017","unstructured":"Dumoitier N, Chaigne B, R\u00e9gent A et al (2017) Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor \u03b2 and activate fibroblasts. Arthritis Rheumatol 69:1078\u20131089. https:\/\/doi.org\/10.1002\/art.40016","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita T, Kobayashi T, Mizumaki K et al (2018) Baff inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv 4:eaas9944. https:\/\/doi.org\/10.1126\/sciadv.aas9944","journal-title":"Sci Adv"},{"key":"1065_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930970","volume":"13","author":"A Chepy","year":"2022","unstructured":"Chepy A, Bourel L, Koether V et al (2022) Can antinuclear antibodies have a pathogenic role in systemic sclerosis? Front Immunol 13:930970. https:\/\/doi.org\/10.3389\/fimmu.2022.930970","journal-title":"Front Immunol"},{"key":"1065_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150123","volume":"720","author":"CK May","year":"2024","unstructured":"May CK, Noble PW, Herzog EL et al (2024) Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation. Biochem Biophys Res Commun 720:150123. https:\/\/doi.org\/10.1016\/j.bbrc.2024.150123","journal-title":"Biochem Biophys Res Commun"},{"key":"1065_CR91","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","volume":"20","author":"E Raschi","year":"2018","unstructured":"Raschi E, Chighizola CB, Cesana L et al (2018) Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Res Ther 20:187. https:\/\/doi.org\/10.1186\/s13075-018-1689-6","journal-title":"Arthritis Res Ther"},{"key":"1065_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02360-3","volume":"22","author":"E Raschi","year":"2020","unstructured":"Raschi E, Privitera D, Bodio C et al (2020) Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Res Ther 22:265. https:\/\/doi.org\/10.1186\/s13075-020-02360-3","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1065_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103016","volume":"21","author":"E Chalayer","year":"2022","unstructured":"Chalayer E, Gramont B, Zekre F et al (2022) Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases. Autoimmun Rev 21(3):103016. https:\/\/doi.org\/10.1016\/j.autrev.2021.103016","journal-title":"Autoimmun Rev"},{"key":"1065_CR94","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/art.41243","volume":"72","author":"R Bhandari","year":"2020","unstructured":"Bhandari R, Ball MS, Martyanov V et al (2020) Profibrotic activation of human macrophages in systemic sclerosis. Arthritis Rheumatol 72:1160\u20131169. https:\/\/doi.org\/10.1002\/art.41243","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Lelong M, Jeljeli M et al (2020) Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 178:114103. https:\/\/doi.org\/10.1016\/j.bcp.2020.114103","journal-title":"Biochem Pharmacol"},{"key":"1065_CR96","doi-asserted-by":"publisher","unstructured":"Numajiri H, Kuzumi A, Fukasawa T, et al. B cell depletion inhibits fibrosis via suppressing pro-fibrotic macrophage differentiation in a mouse model of systemic sclerosis. Arthritis Rheumatol. Published Online First: 5 May 2021. https:\/\/doi.org\/10.1002\/art.41798","DOI":"10.1002\/art.41798"},{"key":"1065_CR97","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S et al (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 77:1362\u20131371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213031","journal-title":"Ann Rheum Dis"},{"key":"1065_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100140","volume":"1","author":"X Gao","year":"2020","unstructured":"Gao X, Jia G, Guttman A et al (2020) Osteopontin links myeloid activation and disease progression in systemic sclerosis. Cell Rep Med 1:100140. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100140","journal-title":"Cell Rep Med"},{"key":"1065_CR99","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.41813","volume":"74","author":"D Xue","year":"2022","unstructured":"Xue D, Tabib T, Morse C et al (2022) Expansion of Fc\u03b3 receptor IIIa-positive macrophages, ficolin 1-positive monocyte-derived dendritic cells, and plasmacytoid dendritic cells associated with severe skin disease in systemic sclerosis. Arthritis Rheumatol 74:329\u2013341. https:\/\/doi.org\/10.1002\/art.41813","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR100","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s10067-017-3597-6","volume":"36","author":"A Lescoat","year":"2017","unstructured":"Lescoat A, Lecureur V, Roussel M et al (2017) CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol 36:1649\u20131654. https:\/\/doi.org\/10.1007\/s10067-017-3597-6","journal-title":"Clin Rheumatol"},{"key":"1065_CR101","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/imcb.12217","volume":"97","author":"A Ballerie","year":"2019","unstructured":"Ballerie A, Lescoat A, Augagneur Y et al (2019) Efferocytosis capacities of blood monocyte-derived macrophages in systemic sclerosis. Immunol Cell Biol 97:340\u2013347. https:\/\/doi.org\/10.1111\/imcb.12217","journal-title":"Immunol Cell Biol"},{"key":"1065_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.12.018","volume":"132","author":"B Skaug","year":"2020","unstructured":"Skaug B, Assassi S (2020) Type I interferon dysregulation in systemic sclerosis. Cytokine 132:154635. https:\/\/doi.org\/10.1016\/j.cyto.2018.12.018","journal-title":"Cytokine"},{"key":"1065_CR103","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrrheum.2010.102","volume":"6","author":"M Trojanowska","year":"2010","unstructured":"Trojanowska M (2010) Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6:453\u2013460. https:\/\/doi.org\/10.1038\/nrrheum.2010.102","journal-title":"Nat Rev Rheumatol"},{"key":"1065_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004005","volume":"11","author":"JM Mahoney","year":"2015","unstructured":"Mahoney JM, Taroni J, Martyanov V et al (2015) Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol 11:e1004005. https:\/\/doi.org\/10.1371\/journal.pcbi.1004005","journal-title":"PLoS Comput Biol"},{"key":"1065_CR105","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1136\/annrheumdis-2018-213257","volume":"77","author":"C Crescioli","year":"2018","unstructured":"Crescioli C, Corinaldesi C, Riccieri V et al (2018) Association of circulating CXCL10 and CXCL11 with systemic sclerosis. Ann Rheum Dis 77:1845\u20131846. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213257","journal-title":"Ann Rheum Dis"},{"key":"1065_CR106","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159566","volume":"7","author":"D Khanna","year":"2022","unstructured":"Khanna D, Padilla C, Tsoi LC et al (2022) Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight 7:e159566. https:\/\/doi.org\/10.1172\/jci.insight.159566","journal-title":"JCI Insight"},{"key":"1065_CR107","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557\u2013567. https:\/\/doi.org\/10.1172\/JCI31139","journal-title":"J Clin Invest"},{"key":"1065_CR108","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","volume":"16","author":"B Hinz","year":"2020","unstructured":"Hinz B, Lagares D (2020) Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol 16:11\u201331. https:\/\/doi.org\/10.1038\/s41584-019-0324-5","journal-title":"Nat Rev Rheumatol"},{"key":"1065_CR109","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.40934","volume":"71","author":"V Martyanov","year":"2019","unstructured":"Martyanov V, Whitfield ML, Varga J (2019) Senescence signature in skin biopsies from systemic sclerosis patients treated with senolytic therapy: potential predictor of clinical response? Arthritis Rheumatol 71:1766\u20131767. https:\/\/doi.org\/10.1002\/art.40934","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR110","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho YY, Lagares D, Tager AM et al (2014) Fibrosis\u2013a lethal component of systemic sclerosis. Nat Rev Rheumatol 10:390\u2013402. https:\/\/doi.org\/10.1038\/nrrheum.2014.53","journal-title":"Nat Rev Rheumatol"},{"key":"1065_CR111","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S et al (2020) Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol 72:125\u2013136. https:\/\/doi.org\/10.1002\/art.41055","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103314","volume":"22","author":"S Keret","year":"2023","unstructured":"Keret S, Rimar D, Lansiaux P et al (2023) Differentially expressed genes in systemic sclerosis: towards predictive medicine with new molecular tools for clinicians. Autoimmun Rev 22:103314. https:\/\/doi.org\/10.1016\/j.autrev.2023.103314","journal-title":"Autoimmun Rev"},{"key":"1065_CR113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/annrheumdis-2023-eular.1383","volume":"82","author":"FD Galdo","year":"2023","unstructured":"Galdo FD, Lescoat A, Conaghan PG et al (2023) OP0234\u20052023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS. Ann Rheum Dis 82:154\u2013155. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.1383","journal-title":"Ann Rheum Dis"},{"key":"1065_CR114","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1136\/ard.2007.069518","volume":"66","author":"PJ Clements","year":"2007","unstructured":"Clements PJ, Roth MD, Elashoff R et al (2007) Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 66:1641\u20131647. https:\/\/doi.org\/10.1136\/ard.2007.069518","journal-title":"Ann Rheum Dis"},{"key":"1065_CR115","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"1065_CR116","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas R, Tashkin DP, Furst DE et al (2018) Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res Hoboken 70:439\u2013444. https:\/\/doi.org\/10.1002\/acr.23282","journal-title":"Arthritis Care Res Hoboken"},{"key":"1065_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70004","volume":"7","author":"B White","year":"2025","unstructured":"White B, Furst DE, Frech TM et al (2025) Comparative efficacy of immunosuppressive therapies in the treatment of diffuse cutaneous systemic sclerosis. ACR Open Rheumatol 7:e70004. https:\/\/doi.org\/10.1002\/acr2.70004","journal-title":"ACR Open Rheumatol"},{"key":"1065_CR118","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","volume":"40","author":"GSRSNK Naidu","year":"2020","unstructured":"Naidu GSRSNK, Sharma SK, Adarsh MB et al (2020) Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial. Rheumatol Int 40:207\u2013216. https:\/\/doi.org\/10.1007\/s00296-019-04481-8","journal-title":"Rheumatol Int"},{"key":"1065_CR119","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH van den Hoogen","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ et al (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35:364\u2013372. https:\/\/doi.org\/10.1093\/rheumatology\/35.4.364","journal-title":"Br J Rheumatol"},{"key":"1065_CR120","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378:498\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(11)60982-3","journal-title":"Lancet"},{"key":"1065_CR121","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311:2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"JAMA"},{"key":"1065_CR122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L et al (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378:35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327","journal-title":"N Engl J Med"},{"key":"1065_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(21)00107-7","journal-title":"Lancet Rheumatol"},{"key":"1065_CR124","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630\u20132640. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"1065_CR125","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8:963\u2013974. https:\/\/doi.org\/10.1016\/S2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"key":"1065_CR126","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.41933","volume":"74","author":"D Khanna","year":"2022","unstructured":"Khanna D, Lescoat A, Roofeh D et al (2022) Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice. Arthritis Rheumatol 74:13\u201327. https:\/\/doi.org\/10.1002\/art.41933","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR127","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380:2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"issue":"18","key":"1065_CR128","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381(18):1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"1065_CR129","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla E, Hatron P-Y, Carpentier P et al (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 75:1009\u20131015. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207001","journal-title":"Ann Rheum Dis"},{"key":"1065_CR130","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338. https:\/\/doi.org\/10.1136\/ard.2010.130658","journal-title":"Ann Rheum Dis"},{"key":"1065_CR131","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Gali\u00e8 N, Barber\u00e0 JA et al (2017) Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 76:1219\u20131227. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210236","journal-title":"Ann Rheum Dis"},{"key":"1065_CR132","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373:2522\u20132533. https:\/\/doi.org\/10.1056\/NEJMoa1503184","journal-title":"N Engl J Med"},{"key":"1065_CR133","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, Gali\u00e8 N, Grimminger F et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330\u2013340. https:\/\/doi.org\/10.1056\/NEJMoa1209655","journal-title":"N Engl J Med"},{"key":"1065_CR134","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA et al (2023) Phase 3 trial of Sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 388:1478\u20131490. https:\/\/doi.org\/10.1056\/NEJMoa2213558","journal-title":"N Engl J Med"},{"key":"1065_CR135","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66:940\u2013944. https:\/\/doi.org\/10.1136\/ard.2006.066068","journal-title":"Ann Rheum Dis"},{"key":"1065_CR136","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","volume":"113","author":"VD Steen","year":"1990","unstructured":"Steen VD, Costantino JP, Shapiro AP et al (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352\u2013357. https:\/\/doi.org\/10.7326\/0003-4819-113-5-352","journal-title":"Ann Intern Med"},{"key":"1065_CR137","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez107.047","volume":"58","author":"A Carriero","year":"2019","unstructured":"Carriero A, Abignano G, Hutchinson M et al (2019) 231\u2003Serum interferon score predicts clinical outcome at 12 months in diffuse cutaneous systemic sclerosis as measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS). Rheumatology 58:kez107.047. https:\/\/doi.org\/10.1093\/rheumatology\/kez107.047","journal-title":"Rheumatology"},{"key":"1065_CR138","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2023.02.061","volume":"89","author":"T Fukasawa","year":"2023","unstructured":"Fukasawa T, Yoshizaki A, Ebata S et al (2023) Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial. J Am Acad Dermatol 89:366\u2013369. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.061","journal-title":"J Am Acad Dermatol"},{"key":"1065_CR139","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2022-eular.2519","volume":"81","author":"T Fukasawa","year":"2022","unstructured":"Fukasawa T, Yoshizaki A, Kagebayashi H et al (2022) POS0881\u2005EFFICACY AND SAFETY OF SUBCUTANEOUS BRODALUMAB, A FULLY HUMAN ANTI\u2013IL-17RA MONOCLONAL ANTIBODY, FOR SYSTEMIC SCLEROSIS WITH MODERATE-TO-SEVERE SKIN THICKENING: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 STUDY. Ann Rheum Dis 81:736\u2013736. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.2519","journal-title":"Ann Rheum Dis"},{"key":"1065_CR140","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","volume":"11","author":"RJ Benschop","year":"2019","unstructured":"Benschop RJ, Chow C-K, Tian Y et al (2019) Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs 11:1175\u20131190. https:\/\/doi.org\/10.1080\/19420862.2019.1624463","journal-title":"MAbs"},{"key":"1065_CR141","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM et al (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 70:308\u2013316. https:\/\/doi.org\/10.1002\/art.40358","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR142","doi-asserted-by":"publisher","first-page":"1219760","DOI":"10.3389\/fphar.2023.1219760","volume":"14","author":"FE Herrmann","year":"2023","unstructured":"Herrmann FE, Hesslinger C, Wollin L et al (2023) Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol 14:1219760. https:\/\/doi.org\/10.3389\/fphar.2023.1219760","journal-title":"Front Pharmacol"},{"key":"1065_CR143","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb M, Crestani B, Maher TM (2023) Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev 32:220206. https:\/\/doi.org\/10.1183\/16000617.0206-2022","journal-title":"Eur Respir Rev"},{"key":"1065_CR144","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13753","volume":"6","author":"TH Sisson","year":"2018","unstructured":"Sisson TH, Christensen PJ, Muraki Y et al (2018) Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiol Rep 6:e13753. https:\/\/doi.org\/10.14814\/phy2.13753","journal-title":"Physiol Rep"},{"key":"1065_CR145","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","volume":"76","author":"C Maier","year":"2017","unstructured":"Maier C, Ramming A, Bergmann C et al (2017) Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis 76:1133\u20131141. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210189","journal-title":"Ann Rheum Dis"},{"key":"1065_CR146","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi L, Azuma A, Cottin V et al (2022) Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med 386:2178\u20132187. https:\/\/doi.org\/10.1056\/NEJMoa2201737","journal-title":"N Engl J Med"},{"key":"1065_CR147","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V et al (2025) Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med 392:2193\u20132202. https:\/\/doi.org\/10.1056\/NEJMoa2414108","journal-title":"N Engl J Med"},{"issue":"22","key":"1065_CR148","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher TM, Assassi S, Azuma A et al (2025) Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med 392(22):2203\u20132214. https:\/\/doi.org\/10.1056\/NEJMoa2503643","journal-title":"N Engl J Med"},{"key":"1065_CR149","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218447","author":"Y Allanore","year":"2020","unstructured":"Allanore Y, Wung P, Soubrane C et al (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218447","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1065_CR150","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2402494","volume":"21","author":"A Lescoat","year":"2024","unstructured":"Lescoat A, Ghosh M, Kadauke S et al (2024) Innovative cell therapies for systemic sclerosis: available evidence and new perspectives. Expert Rev Clin Immunol 21(1):29. https:\/\/doi.org\/10.1080\/1744666X.2024.2402494","journal-title":"Expert Rev Clin Immunol"},{"key":"1065_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.04.008","volume":"484","author":"\u00c1 Sz\u00f6\u0151r","year":"2020","unstructured":"Sz\u00f6\u0151r \u00c1, T\u00f3th G, Zsebik B et al (2020) Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR t cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett 484:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2020.04.008","journal-title":"Cancer Lett"},{"key":"1065_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1365172","volume":"15","author":"L Nagy","year":"2024","unstructured":"Nagy L, Mez\u0151si-Csapl\u00e1r M, Rebenku I et al (2024) Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC. Front Immunol 15:1365172. https:\/\/doi.org\/10.3389\/fimmu.2024.1365172","journal-title":"Front Immunol"},{"key":"1065_CR153","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L et al (2024) CD19 CAR t-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"1065_CR154","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt W, Freitag M, Claus M et al (2024) Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83:543\u2013546. https:\/\/doi.org\/10.1136\/ard-2023-225174","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"1065_CR155","doi-asserted-by":"publisher","first-page":"00701","DOI":"10.1016\/j.cell.2024.06.027","volume":"S0092\u20138674","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell S0092\u20138674(24):00701\u201300703. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"key":"1065_CR156","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","volume":"4","author":"D Farge","year":"2022","unstructured":"Farge D, Loisel S, Resche-Rigon M et al (2022) Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study. Lancet Rheumatol 4:e91-104. https:\/\/doi.org\/10.1016\/S2665-9913(21)00326-X","journal-title":"Lancet Rheumatol"},{"key":"1065_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102755","volume":"20","author":"D Farge","year":"2021","unstructured":"Farge D, Loisel S, Lansiaux P et al (2021) Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmun Rev 20:102755. https:\/\/doi.org\/10.1016\/j.autrev.2021.102755","journal-title":"Autoimmun Rev"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-025-01065-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-025-01065-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-025-01065-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:31:51Z","timestamp":1778661111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-025-01065-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s00281-025-01065-6","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AL:\n                      no competing Interests.\n                      VL:\n                      no competing Interests.\n                      JEG:\n                      JEG has received Grant support from Celgene\/BMS, Janssen, Eli Lilly, and Almirall. LCT has received support from Novartis, Janssen and Galderma. JEG has served on advisory boards for AstraZeneca, Sanofi, Eli Lilly, Boehringer Ingelheim, Novartis, Janssen, Almirall, BMS.\n                      DK:\n                      Consulting fees from Abbvie, Amgen, Argenx, Boehringer Ingelheim, Bristol Myers Squibb, Cabaletta Bio, Certa, Merck, Zura Bio, grants or contracts from NIH RO1, Department of Defense, Boehringer Ingelheim, Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}